Cardiovascular disorders. Primary prevention.
Murphy
Michael
M
University of Oxford, Oxford, UK.
Foster
Charles
C
Sudlow
Cathie
C
Nicholas
Julian
J
Mulrow
Cindy
C
Ness
Andy
A
Pignone
Michael
M
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001572:Benzofurans; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003131:Combined Modality Therapy; D015444:Exercise; D005247:Feeding Behavior; D006801:Humans; D008019:Life Style; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016540:Smoking Cessation
C402242:((2-butyl-3-benzofuranyl)-(5-(2-diethylamino)ethoxy)-2-thienyl)methanone; D001572:Benzofurans; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin